Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 5:8:F1000 Faculty Rev-257.
doi: 10.12688/f1000research.15974.1. eCollection 2019.

Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?

Maura Corsetti  1   2 , Jasper Pannemans  3 , Peter Whorwell  4
Affiliations
Review

Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?

Maura Corsetti et al. F1000Res. .

Abstract

Opioids have recently received much attention because of the epidemic in their use in some countries such as the USA and the UK. Concerns have been raised about the possibility that they can increase mortality in patients when used on a long-term basis. Moreover, they are known to induce paradoxical hyperalgesia as well as alterations of gut function. The analgesic properties of opioids are mediated by receptors located in the brain, but as opioid receptors are also expressed in the gastrointestinal tract, new drugs acting on these receptors have recently been developed to treat two functional disorders, namely irritable bowel syndrome with diarrhoea and opioid-induced constipation. The aim of this article is to highlight some interesting observations resulting from the development of these drugs in the field of functional gastrointestinal disorders.

Keywords: PAMORA; eluxadoline; mu opioid receptors; opioids.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Manchikanti L, Helm S, 2nd, Fellows B, et al. : Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38. - PubMed
    1. Burr NE, Smith C, West R, et al. : Increasing Prescription of Opiates and Mortality in Patients With Inflammatory Bowel Diseases in England. Clin Gastroenterol Hepatol. 2018;16(4):534–541.e6. 10.1016/j.cgh.2017.10.022 - DOI - PubMed

    2. F1000 Recommendation

    1. Sternini C, Patierno S, Selmer IS, et al. : The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16 Suppl 2:3–16. 10.1111/j.1743-3150.2004.00553.x - DOI - PubMed
    1. Pannemans J, Corsetti M: Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders? Curr Opin Pharmacol. 2018;43:53–8. 10.1016/j.coph.2018.08.008 - DOI - PubMed
    1. Nee J, Rangan V, Lembo A: Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract. Neurogastroenterol Motil. 2018;30(5):e13367. 10.1111/nmo.13367 - DOI - PubMed

    2. F1000 Recommendation

MeSH terms